Bill is the Co-chair of the Life Sciences Practice Group. He has extensive experience representing issuers, investors, and investment banks in structuring and executing IPOs, cross-over investments, alternative public offerings, including APOs, reverse mergers and Form 10 transactions, follow-on public offerings, CMPOs, registered directs, PIPEs, and private placements. Bill represents hedge funds, venture capital firms, and private equity firms in customized investments in public companies, including structured PIPEs and registered directs. Bill also represents public companies in public and private financings, SEC compliance, corporate governance, and general counseling.
Bill has extensive experience representing buyers and sellers in M&A transactions, including public company deals, private company deals, and spin-offs. Bill regularly represents domestic and foreign companies, and he is well-versed in issues specific to cross-border deals.
Additionally, Bill represents private companies and investors in venture capital transactions.
viewpoints
Frequently Asked Questions for Private Companies Considering a Reverse Merger
February 13, 2024 | Article | By William Hicks, John T. Rudy
Reverse mergers aren’t an alternative to an IPO, rather they can be a strategic approach for companies looking to go public by leveraging “fallen angels”. Mintz Members Bill Hicks and John Rudy answer frequently asked questions for private companies considering a reverse merger in an article featured in PitchBook’s 2023 Annual US VC Valuations Report. The authors detail the benefits and challenges associated with a reverse merger including finding partners, PIPE financing, Nasdaq access for non-US companies, and SEC implications.
News & Press
Mintz advised the underwriters in connection with a $90 million underwritten offering by Rezolute, Inc. of 20,786,923 shares of common stock and pre-funded warrants to purchase up to 6,905,385 shares of common stock. The common stock is listed on the Nasdaq Capital Market under the symbol “RZLT.”
Life Sciences Practice Co-chair William Hicks was featured in Pharmaceutical Technology following his participation as a panelist at the OBN BioTrinity 2025 conference in London, which focused on how US uncertainty is impacting the biopharma environment.
The Business of Biotech
November 29, 2024
Bill Hicks, Co-chair of Mintz's Life Sciences practice, recently appeared on “The Life Sci Fantastic,” a podcast with Eliot Forster, that dives into the science behind life-changing biotech breakthroughs.
Thomson Reuters Recognizes 10 Mintz Attorneys as “Stand-out Lawyers”
February 20, 2024
Mintz is pleased to share 10 attorneys have been named by their clients as Thomson Reuters “Stand-out Lawyers.”
BOSTON – Mintz has earned top rankings in the 2023 edition of Legal 500 United States guide. The firm is recognized in 14 practice categories, and 59 individual attorneys are also recognized in the guide, some in more than one category.
Securities & Capital Markets Co-Chair William Hicks spoke to The Boston Business Journal about the burnout of the SPAC market.
Deal Watch: Where Did All the IPOs Go?
September 26, 2022
Spotlight on SPACs: The Dog Days of Summer
August 10, 2022
Mintz Practice Groups and Attorneys Garner Top Rankings in 2020 Edition of The Legal 500 United States
June 12, 2020
podcasts
Between the Biotech Waves Conversation with William Hicks
April 16, 2025 | Podcast
The Life Sci Fantastic Podcast - The Business of Biotech
November 28, 2024 | Podcast
A Between The Biotech Waves Conversation With William Hicks
June 10, 2022 | Podcast
Bill Hicks was a guest on Between the Biotech Waves with Nessan Bermingham.
Events & Speaking
Navigating the Path to IPO: Preparing Your Biotech Company for the Public Markets
Investival Showcase USA
Miami, FL
Navigating Biotech Funding Dynamics: Is Flat the New Up? Shifts in Public and Private Finance
LSX Inv€$tival Showcase™
London, UK
The Next Phase In US Healthcare Investment – What Have We Seen, And Where Are We Going?
LSX Investival Showcase
Virtual Event
Sustainable Ecosystem for Bio/MedTech Startups
12th New York Health Forum
Yale Club Manhattan, Trumbull & Saybrook Room, 18th Floor
Boston Biotech CEO Conference
Boston Biotech Conferences
Four Seasons Hotel, 200 Boylston Street, Boston, MA
Recognition & Awards
Recommended by The Legal 500 United States for Healthcare: Life Sciences (2020); Capital Markets: Equity (2021 – 2022, 2024)
Who’s Who Legal: Global Leader - Life Sciences (2023)
Thomson Reuters Stand-out Lawyers (2024)
Who’s Who Legal: Life Sciences: Transactional (2019)
LMG Life Sciences: Financial & Corporate, Corporate, Mergers & Acquisitions, Venture Capital US Life Sciences Star (2018-2019)
Ranked in Healthcare & Life Sciences - Transactional, Lexology Index 2025
Recent Insights
Mintz advised the underwriters in connection with a $90 million underwritten offering by Rezolute, Inc. of 20,786,923 shares of common stock and pre-funded warrants to purchase up to 6,905,385 shares of common stock. The common stock is listed on the Nasdaq Capital Market under the symbol “RZLT.”
Between the Biotech Waves Conversation with William Hicks
April 16, 2025| Podcast|
Life Sciences Practice Co-chair William Hicks was featured in Pharmaceutical Technology following his participation as a panelist at the OBN BioTrinity 2025 conference in London, which focused on how US uncertainty is impacting the biopharma environment.
